Skip Navigation


Rheumatology Advance Access originally published online on January 3, 2008
Rheumatology 2008 47(2):172-175; doi:10.1093/rheumatology/kem344
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
47/2/172    most recent
kem344v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Koca, S. S.
Right arrow Articles by Metin, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Koca, S. S.
Right arrow Articles by Metin, K.
Related Collections
Right arrow Systemic Sclerosis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Effectiveness of etanercept in bleomycin-induced experimental scleroderma

S. S. Koca1, A. Isik1, I. H. Ozercan2, B. Ustundag3, B. Evren1 and K. Metin3

1Department of Rheumatology, 2Department of Pathology and 3Department of Biochemistry, Faculty of Medicine, Firat University, Elazig, Turkey.

Correspondence to: S. S. Koca, Firat University, Firat Tip Merkezi, Ic Hastaliklari AD./Romatoloji BD., 23119-Elazig, Turkey. E-mail: kocassk{at}yahoo.com


  Abstract

Objectives. To evaluate the effects of etanercept and thalidomide in the mouse model of bleomycin-induced scleroderma (BLM-IS).

Methods. This study involved four groups (n = 8 mice in each group). Dermal sclerosis was induced by repeated subcutaneous injections of BLM (10 µg) for 4 weeks in BALB/c mice. Control group received only phosphate-buffered saline. The second group received only BLM; the third and fourth groups were also given an intraperitoneal injection of 100 µg etanercept or 150 mg/kg thalidomide, respectively.

Results. BLM increased serum TGF-β1, tissue hydroxyproline levels and expression of {alpha}-smooth muscle actin ({alpha}-SMA), and dermal fibrosis was histopathologically prominent. Although thalidomide had no significant effect, etanercept caused decreases in levels of serum TGF-β1, tissue hydroxyproline and number of {alpha}-SMA-positive cells.

Conclusion. Inhibition of TNF-{alpha} with etanercept in BLM-IS was resulted in a significant reduction of the dermal sclerosis, collagen accumulation and the number of infiltrating myofibroblastic cells. TNF-{alpha} may play a key role in the progression of BLM-IS and TNF-{alpha} antagonists may be useful in the management of scleroderma.

KEY WORDS: Scleroderma, Bleomycin, Etanercept, Animal model

Submitted 25 July 2007; revised version accepted 19 November 2007.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.